Patents by Inventor Frederick Ryckman

Frederick Ryckman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10363258
    Abstract: Provided herein are prostaglandin F2? analog compositions and methods for treating migraines.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: July 30, 2019
    Assignee: Manistee Partners LLC
    Inventors: Robert L. Bratzler, Martin Wand, Frederick Ryckman, Bradford J. Shingleton
  • Publication number: 20190022105
    Abstract: Provided herein are prostaglandin F2? analog compositions and methods for treating migraines.
    Type: Application
    Filed: January 3, 2018
    Publication date: January 24, 2019
    Inventors: Robert L. Bratzler, Martin Wand, Frederick Ryckman, Bradford J. Shingleton
  • Publication number: 20180193354
    Abstract: Provided herein are prostaglandin F2? analog compositions and methods for treating migraines.
    Type: Application
    Filed: January 3, 2018
    Publication date: July 12, 2018
    Inventors: Robert L. Bratzler, Martin Wand, Frederick Ryckman, Bradford J. Shingleton
  • Patent number: 9913849
    Abstract: Provided herein are prostaglandin F2alpha analog compositions and methods for treating migraines by topical administration. The method involves administering topically to a subject in need thereof a composition including a prostaglandin F2apha analog or pharmaceutically acceptable salt thereof, in an amount effective to treat migraine. The treatment may be administered prophylactically or therapeutically. Topical administration is to the epidermis, conjunctival surface or other mucous membranes, typically to a nail, the skin, the hair, the surface of the eye or the inner surface of the eyelid, and the like. The prostaglandin F2a analog can be latanoprost, isopropyl unoprostone, bimatoprost, travoprost, or tafluprost; or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: March 13, 2018
    Assignee: Manistee Partners LLC
    Inventors: Robert L. Bratzler, Martin Wand, Frederick Ryckman, Bradford J. Shingleton
  • Publication number: 20160324870
    Abstract: Provided herein are prostaglandin F2alpha analog compositions and methods for treating migraines by topical administration. The method involves administering topically to a subject in need thereof a composition including a prostaglandin F2apha analog or pharmaceutically acceptable salt thereof, in an amount effective to treat migraine. The treatment may be administered prophylactically or therapeutically. Topical administration is to the epidermis, conjunctival surface or other mucous membranes, typically to a nail, the skin, the hair, the surface of the eye or the inner surface of the eyelid, and the like. The prostaglandin F2a analog can be latanoprost, isopropyl unoprostone, bimatoprost, travoprost, or tafluprost; or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 9, 2015
    Publication date: November 10, 2016
    Applicant: Manistee Partners LLC
    Inventors: Robert L. Bratzler, Martin Wand, Frederick Ryckman, Bradford J. Shingleton
  • Publication number: 20110087502
    Abstract: Methods, systems, devices and/or apparatus related to predicting availability of medical facility beds. Specifically, the disclosed methods, systems, devices and/or apparatus relate to determining which beds in the medical facility are available or unavailable at specific time periods (including past, present and/or future time periods).
    Type: Application
    Filed: October 13, 2010
    Publication date: April 14, 2011
    Inventors: PAUL A. YELTON, Frederick Ryckman